Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force

B Vellas,R Fielding,S Bhasin,F Cerreta,B Goodpaster,J M Guralnik,S Kritchevsky,V Legrand,C Forkin,J Magaziner,J E Morley,L Rodriguez-Manas,R Roubenoff,S Studenski,D T Villareal,M Cesari,International Conference on Frailtyand Sarcopenia Research Task Force,S Andrieu,P Belissa-Mathiot,A Bellamine,R Bernabei,J Cedarbaum,C Cesari,R Correa-de-Araujo,S Del Signore,W Dioh,S Donahue,W Goodpaster,J Guralnick,J Harp,M Hoehne,M Kashiwa,T Klompenhouwer,C Mejia,B Morgan,J Morley,V Mustad,D Neil,D Papanicolaou,S Pereira,R Pordy,C Rinsch,R Rolland,A Russell,P P Sagnier,P Schüler,A Singh,M Tian,J Touchon,T Travison,V Vellas,S Verlaan,D Villareal,T Webb,S Wijers

DOI: https://doi.org/10.14283/jfa.2016.110

Abstract:Muscle atrophy occurs as a consequence of a number of conditions, including cancer, chronic obstructive pulmonary disease (COPD), diabetes mellitus, heart failure, and other chronic diseases, where it is generally a predictor of poor survival. It also occurs as a consequence of disuse and an age-related loss of muscle mass and strength (sarcopenia). The aims of the 2016, International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force were to examine how these specific chronic conditions have been employed in treatment trials thus far and how future trials using these patient groups might be designed for efficient identification of effective sarcopenia interventions. Functional limitations assessed as gait speed, distance walked over a set time period, or other attributes of physical performance have been suggested as outcome measures in sarcopenia trials. Indeed, such measures have already been used successfully in a number of trials aimed at preventing disability in older adults.